Periodic Fever Syndrome - Articles and news items

Novartis-Periodic Fever Syndrome

Novartis’ Ilaris provides hope for Periodic Fever Syndrome patients

Industry news / 27 April 2016 / Mandy Parrett, Editorial Assistant

Novartis announced today that the FDA has granted three breakthrough therapy designations for Ilaris® (canakinumab) to treat rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...